Karyopharm Therapeutics Inc.
KPTI
$5.40
$0.459.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -76.42M | -87.48M | -89.91M | -146.34M | -143.10M |
| Total Depreciation and Amortization | 340.00K | 336.00K | 333.00K | 325.00K | 530.00K |
| Total Amortization of Deferred Charges | 6.37M | 4.23M | 2.03M | 821.00K | 814.00K |
| Total Other Non-Cash Items | -57.47M | -46.43M | -41.94M | 17.40M | 17.61M |
| Change in Net Operating Assets | -302.00K | 9.09M | -843.00K | 10.25M | 31.42M |
| Cash from Operations | -127.49M | -120.26M | -130.34M | -117.54M | -92.72M |
| Capital Expenditure | -142.00K | -195.00K | -195.00K | -195.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.62M | 107.71M | 92.56M | 62.46M | 7.94M |
| Cash from Investing | 95.47M | 107.52M | 92.36M | 62.27M | 7.94M |
| Total Debt Issued | 83.30M | 83.30M | -- | -- | -- |
| Total Debt Repaid | -40.52M | -40.52M | -- | -- | -- |
| Issuance of Common Stock | 1.45M | 1.04M | 1.04M | 1.12M | 1.12M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.59M | -2.59M | 40.19M | -- | -- |
| Cash from Financing | 41.65M | 41.23M | 41.23M | 1.12M | 1.12M |
| Foreign Exchange rate Adjustments | -11.00K | 98.00K | 10.00K | -5.00K | -34.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.62M | 28.59M | 3.26M | -54.15M | -83.69M |